Jeannine Villella, DO
Gynecologic Oncology · New York, NYNPI 1659321982
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by AstraZeneca at 46.2% of the total. Reporting peaked in 2021 at $4,662 and has fallen 75.9% since, to $1,122 in 2025.
Across 32 payments — averaging $208.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Dilon Technologies, Inc.$2K
- Biom'up France SAS$1K
- Smith+Nephew$232
- Innovation Technologies Inc$130
Across 31 payments — averaging $10,947 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$233K
- Merck$106K
What the payments were for
- Consulting fees$3,08346%
- Food & beverage$3,59154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $3,083 |
| Dilon Technologies, Inc. | 16 | $1,741 |
| Biom'up France SAS | 12 | $1,488 |
| Smith+Nephew | 2 | $232 |
| Innovation Technologies Inc | 1 | $130 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$3,083
- HemoBlast Bellows$2,941
- PICO7$140
- Irrisept$130
How this compares
$6,673 in reported general payments places this provider in the 80th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in New York
- Bhavana PothuriNew York$366K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Farr NezhatNew York$41K
- Kristen ZeligsNew York$38K
- Nimesh NagarshethNew York$33K
- Jeff LinNew York$30K
- Valentin KolevNew York$23K
- Jason WrightNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.